## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Werner MEDERSKI et al Examiner: SHAMEEM, Golam M.

Serial No.: 10/594,024 Group Art Unit: 1626

Filed: September 25, 2009

Title: PROLINYL DERIVATIVES FOR THE TREATMENT OF THROMBOSIS

## RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated March 25, 2009, Applicant's hereby elect with traverse Group I, claims 1-8, directed to compounds.

As species, applicants elect, N-1-[(4-Chlorophenyl)]-N-2-{[4-(2-[dimethylaminomethyl]phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

which is compound ("A1") on page 29 in example 1, and is the first compound recited in claim 8.

The specific substituents in the general formula are provided below:

R denotes Hal.

R<sup>1</sup> denotes OH.

R<sup>2</sup> denotes H.

R<sup>3</sup> denotes H.

1 Merck-3237